1. Hypersensitivity to any drugs/metabolites as ruxolitinib. 2. Presence of severely impaired renal function. 3. Suspected uncontrolled, active bacterial, fungal, viral, or other infection. 4. Current or history of active TB infection. 5. History of progressive multifocal leukoencephalopathy. 6. Intubated between screening and randomization. 7. In ICU at time of randomization. 8. Patients who are on anti-rejection, immunosuppressant or immunomodulatory drugs. 9. Intubated or in ICU for COVID-19 disease prior to screening. 10. Participating in any other investigational trials. 11. Unable to ingest tablets at randomization. 12. ALT &#8805, 5 x ULN at screening. 13. Evidence of liver cirrhosis (Child A to C). 14. ANC < 1000/&#956,L at screening. 15. Platelet count < 50,000/&#956,L at screening. 16. Pregnant or nursing (lactating) women. 17. Females of childbearing potential unless the use of highly effective contraception method.

1. Hypersensitivity to any drugs/metabolites as ruxolitinib. 2. Presence of severely impaired renal function. 3. Suspected uncontrolled, active bacterial, fungal, viral, or other infection. 4. Current or history of active TB infection. 5. History of progressive multifocal leukoencephalopathy. 6. Intubated between screening and randomization. 7. In ICU at time of randomization. 8. Patients who are on anti-rejection, immunosuppressant or immunomodulatory drugs. 9. Intubated or in ICU for COVID-19 disease prior to screening. 10. Participating in any other investigational trials. 11. Unable to ingest tablets at randomization. 12. ALT &#8805, 5 x ULN at screening. 13. Evidence of liver cirrhosis (Child A to C). 14. ANC < 1000/&#956,L at screening. 15. Platelet count < 50,000/&#956,L at screening. 16. Pregnant or nursing (lactating) women. 17. Females of childbearing potential unless the use of highly effective contraception method.